SG11201502980VA - POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF - Google Patents

POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF

Info

Publication number
SG11201502980VA
SG11201502980VA SG11201502980VA SG11201502980VA SG11201502980VA SG 11201502980V A SG11201502980V A SG 11201502980VA SG 11201502980V A SG11201502980V A SG 11201502980VA SG 11201502980V A SG11201502980V A SG 11201502980VA SG 11201502980V A SG11201502980V A SG 11201502980VA
Authority
SG
Singapore
Prior art keywords
tgfβ
polypeptides derived
polypeptides
derived
Prior art date
Application number
SG11201502980VA
Other languages
English (en)
Inventor
Osorio Ángel De Jesús Corria
Monzón Kalet León
Portilla Tania Carmenate
Meriño Amaury Pupo
Rodríguez Saumel Pérez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502980V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of SG11201502980VA publication Critical patent/SG11201502980VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201502980VA 2012-11-09 2013-10-30 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF SG11201502980VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (1)

Publication Number Publication Date
SG11201502980VA true SG11201502980VA (en) 2015-06-29

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502980VA SG11201502980VA (en) 2012-11-09 2013-10-30 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF

Country Status (28)

Country Link
US (1) US9701730B2 (ru)
EP (1) EP2918284B1 (ru)
JP (2) JP6298823B2 (ru)
KR (1) KR102093494B1 (ru)
CN (1) CN104902916B (ru)
AR (1) AR093391A1 (ru)
AU (1) AU2013344022B2 (ru)
BR (1) BR112015010145B1 (ru)
CA (1) CA2887455C (ru)
CL (1) CL2015001252A1 (ru)
CO (1) CO7400865A2 (ru)
CU (1) CU24181B1 (ru)
EA (1) EA031990B1 (ru)
ES (1) ES2857176T3 (ru)
HK (1) HK1213781A1 (ru)
IL (1) IL238621B (ru)
JO (1) JO3502B1 (ru)
MX (1) MX366060B (ru)
MY (1) MY173078A (ru)
NZ (1) NZ707850A (ru)
PE (1) PE20150890A1 (ru)
PH (1) PH12015500807A1 (ru)
SG (1) SG11201502980VA (ru)
TN (1) TN2015000129A1 (ru)
TW (1) TWI615404B (ru)
UA (1) UA115678C2 (ru)
WO (1) WO2014071894A1 (ru)
ZA (1) ZA201504462B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7079779B2 (ja) * 2016-11-18 2022-06-02 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 操作されたtgfベータ単量体およびtgfベータシグナル伝達のためのそれらの使用
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4572899A (en) * 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2006007509A2 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
WO2006076041A2 (en) * 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
MX2012012229A (es) * 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.

Also Published As

Publication number Publication date
EP2918284B1 (en) 2021-02-17
US20150284441A1 (en) 2015-10-08
UA115678C2 (uk) 2017-12-11
JP6298823B2 (ja) 2018-03-20
AU2013344022B2 (en) 2016-12-15
EP2918284A1 (en) 2015-09-16
BR112015010145A2 (ru) 2017-08-22
MY173078A (en) 2019-12-25
IL238621A0 (en) 2015-06-30
ES2857176T3 (es) 2021-09-28
CA2887455C (en) 2022-05-17
JP6608473B2 (ja) 2019-11-20
AR093391A1 (es) 2015-06-03
TW201431875A (zh) 2014-08-16
AU2013344022A1 (en) 2015-05-28
PE20150890A1 (es) 2015-06-10
CL2015001252A1 (es) 2015-07-17
JP2018111703A (ja) 2018-07-19
CN104902916B (zh) 2018-04-13
MX366060B (es) 2019-06-26
NZ707850A (en) 2019-08-30
TWI615404B (zh) 2018-02-21
ZA201504462B (en) 2018-11-28
EA031990B1 (ru) 2019-03-29
CU20120158A7 (es) 2014-06-27
CO7400865A2 (es) 2015-09-30
MX2015005875A (es) 2015-09-10
JO3502B1 (ar) 2020-07-05
CU24181B1 (es) 2016-04-25
CA2887455A1 (en) 2014-05-15
IL238621B (en) 2019-12-31
US9701730B2 (en) 2017-07-11
CN104902916A (zh) 2015-09-09
HK1213781A1 (zh) 2016-07-15
BR112015010145B1 (pt) 2022-06-07
EA201590914A1 (ru) 2015-09-30
JP2015535000A (ja) 2015-12-07
KR20150083848A (ko) 2015-07-20
WO2014071894A1 (es) 2014-05-15
PH12015500807A1 (en) 2015-06-08
KR102093494B1 (ko) 2020-03-26
TN2015000129A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
IL261632B (en) Chimeric factor viii polypeptides and uses thereof
HK1253343A1 (zh) 新穎縮肽及其用途
HK1210790A1 (en) Modified factor polypeptides and uses thereof
EP2870170A4 (en) NOVEL PEPTIDES AND THEIR USE
GB201201100D0 (en) Polypeptides and methods
SG11201500111VA (en) Peptides and uses thereof
HK1210949A1 (en) Combinations and uses thereof
SG11201501646PA (en) Peptides and their uses
PT2855506T (pt) Péptido e utilização do mesmo
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
HK1201050A1 (en) Polypeptides and their use
IL237400B (en) Rhizobacteria and its uses
HK1213781A1 (zh) 衍生自 β的多肽及其用途
EP2918600A4 (en) NEW PEPTIDE AND ITS USE
GB201214769D0 (en) Methodsa and peptides
GB201210303D0 (en) Polypeptides and methods